South SFV Today

PALO ALTO, C.A. –U.S. Rep. Anna G. Eshoo (CA-16), Ranking Member of the Energy and Commerce Health Subcommittee, introduced the Drug Origin Transparency Act, legislation to help doctors and patients know where drugs and their ingredients are sourced from. The bill would require drug manufacturers to report to the Food and Drug Administration (FDA) quarterly the suppliers they rely on and include on the drug’s public-facing label the name and place of business of the manufacturers of the drug and its active pharmaceutical ingredients.

“The crippling inadequacies of America’s drug supply have become a life-threatening crisis. In order to address critical drug shortages, the FDA, hospitals, and doctors must know where drugs and their ingredients are originally sourced from,” said Rep. Eshoo. “I introduced the Drug Origin Transparency Act to allow the FDA to better monitor the U.S. pharmaceutical supply chain to identify and mitigate potential triggers that could lead to shortages, and help patients make an informed choice between buying a product made in America or one made in India or China.”

Rep. Eshoo has a long history of advocating for drug supply chain transparency. In 2022, she introduced the Improved Transparency of Foreign Drug Manufacturing Act, legislation that directs the FDA to collect additional information on drugs and the active pharmaceutical ingredients that are manufactured overseas.

The bill text is available HERE. 

Original source can be found here